Last reviewed · How we verify
NCT04643977
Assessment of the Safety and Efficacy of the Dermal Filler "mARG-01-17" in Facial Rejuvenation Therapy
NA trial testing mARG-01-17 (mesohyal AGRIBENONE) in Facial Rejuvenation in 40 participants. Completed in 18 December 2018.
18 December 2018
Quick facts
| Lead sponsor | Mesoestetic Pharma Group S.L. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 30 August 2018 |
| Primary completion | 18 December 2018 |
| Estimated completion | 18 December 2018 |
| Sites | 1 location across Bulgaria |
Drugs / interventions tested
- mARG-01-17 (mesohyal AGRIBENONE)
Conditions studied
- Facial Rejuvenation — all drugs for Facial Rejuvenation →
Sponsor
Mesoestetic Pharma Group S.L.
Who can join
Adults 35 to 65, any sex, with Facial Rejuvenation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the clinical investigation is to evaluate the performance of the mARG-01-17 dermal filler in the context of its efficacy and safety.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04643977
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Mesoestetic Pharma Group S.L. trials
Trials by the same sponsor.
- NCT06477432 — Evaluation of the Safety and Performance Characteristics of Mesofiller Mesotox for the Correction of Wrinkles and Rehydr · NA · completed
- NCT06486740 — Evaluation of the Safety and Performance Characteristics of Mesofiller Aox for the Correction of Mild and Moderate Facia · NA · completed
- NCT05450380 — Clinical Investigation to Assess Safety and Performance of Dermal Filler of Hyaluronic Acid · NA · completed
- NCT06482723 — Efficacy and Performance Evaluation of mGlobal L+AS 20 mg/ml Hyaluronic Acid, for the Correction of Light to Moderate Wr · NA · completed
- NCT06451822 — Efficacy and Performance Evaluation of mIntense L+AS 25 mg/ml Hyaluronic Acid for the Correction of Moderate to Deep Wri · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04643977 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mesoestetic Pharma Group S.L.
- Last refreshed: 25 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04643977.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing